SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Akamis Bio to Present Phase 1 NG-348 Data at SITC 2026

Akamis Bio says it will present data from a Phase 1 study of NG-348 in patients with advanced epithelial tumors at SITC 2026.

Related stories